Open Access3 QUESTIONS ON... When Enthusiasm for New Cancer Drugs Is Premature
Author(s) -
Sarah DiGiulio
Publication year - 2021
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000743604.69892.90
Subject(s) - osimertinib , medicine , lung cancer , oncology , clinical trial , clinical endpoint , randomized controlled trial , cancer , family medicine , erlotinib , epidermal growth factor receptor